Ashley Cordova - 06 Jan 2023 Form 4 Insider Report for NovoCure Ltd (NVCR)

Role
Chief Financial Officer
Signature
By: /s/ Steven Robbins, Attorney in Fact for Ashley Cordova
Issuer symbol
NVCR
Transactions as of
06 Jan 2023
Net transactions value
+$4,112
Form type
4
Filing time
10 Jan 2023, 15:18:06 UTC
Previous filing
05 Dec 2022
Next filing
02 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVCR Ordinary Shares Award $4,112 +66 +0.09% $62.30 74,442 06 Jan 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2022 through December 30, 2022. This transaction is also exempt under Rule 16b-3(c).
F2 In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 1, 2022.